An antimicrobial peptide derived from tussah silk fibroin, its preparation method and application

By screening RGD sequence tussah silk fibroin peptides using phosphoric acid hydrolysis and molecular docking technology, the problem of unclear antibacterial activity of tussah silk fibroin peptides was solved, and effective inhibition of Escherichia coli and Staphylococcus aureus and wound repair effects were achieved.

CN122608741BActive Publication Date: 2026-11-17LIAONING ACAD OF MARINE FISHERIES SCI (DALIAN INST OF BIOTECHNOLOGY LIAONING ACAD OF AGRI SCI LIAONING MARINE ENVIRONMENT MONITORING STATION)
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202611040861.1
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2026-07-14
Publication Date
2026-11-17
Estimated Expiration
2046-07-14

AI Technical Summary

Technical Problem

Current technology has not yet clearly defined the core peptide structure and amino acid sequence of tussah silk fibroin peptides that exert antibacterial activity, which limits their precise application in the fields of antibacterial skin care and wound repair.

Method used

Tussilago farfara fibroin mixed peptides were prepared by phosphoric acid hydrolysis. Combined with peptide sequence identification and molecular docking technology, antibacterial peptides with the amino acid sequence RGD were screened out and their binding ability to bacterial receptor proteins was verified, resulting in three antibacterial active peptides.

Benefits of technology

The screened antimicrobial peptides have significant growth-inhibiting effects on Escherichia coli and Staphylococcus aureus, can disrupt bacterial cell membranes, promote wound healing, and provide dual effects of antibacterial and skin repair.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122608741B_ABST
    Figure CN122608741B_ABST
Patent Text Reader

Abstract

This invention discloses an antimicrobial peptide derived from tussah silk fibroin, its preparation method, and its applications, belonging to the field of biotechnology. The amino acid sequence of the antimicrobial peptide is SEQ ID NO:1, SEQ ID NO:2, or SEQ ID NO:3, wherein the antimicrobial peptide shown in SEQ ID NO:1 contains the Arg-Gly-Asp sequence, i.e., the RGD sequence. This invention is the first to screen three antimicrobial active peptides from tussah silk fibroin hydrolysate, which exhibit growth inhibitory effects against both *Escherichia coli* and *Staphylococcus aureus*. They disrupt bacterial cell membrane integrity, causing leakage of intracellular nucleic acids and proteins, thus exerting antimicrobial effects. The antimicrobial peptide containing the RGD sequence shows the best efficacy. The antimicrobial peptide provided by this invention is derived from natural tussah silk fibroin, has good biocompatibility, and can be applied to antimicrobial and anti-inflammatory cosmetics, possessing both antimicrobial and skin repair effects, showing promising application prospects in wound care and problem skin care.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of biotechnology, and in particular to an antimicrobial peptide derived from tussah silk fibroin, its preparation method, and its application. Background Technology

[0002] Tussah silk fibroin peptides are a mixture of bioactive small-molecule peptides prepared by hydrolysis of natural tussah silk fibroin protein. They possess diverse physiological functions and are widely used in skin protection research and applications, exerting effects such as moisturizing, improving the skin barrier, anti-oxidation, delaying aging, and promoting wound healing and repair. Existing research indicates that mixed peptides derived from tussah silk fibroin have a certain inhibitory effect on various Gram-negative and Gram-positive bacteria; however, related studies are limited to the overall level of the mixed peptides, and the specific structure and amino acid sequence of the core peptides that exert antibacterial activity have not yet been clarified.

[0003] The RGD sequence, or arginine-glycine-aspartic acid tripeptide sequence, is a core cell adhesion recognition motif in the fields of biochemistry and biomedicine. It is a crucial cell adhesion recognition site among extracellular matrix proteins such as fibronectin, laminin, and collagen. It can be specifically recognized and bound by integrin receptors on the cell surface, playing an important regulatory role in physiological processes such as cell adhesion and tissue repair. Repeated RGD sequences naturally exist in tussah silk fibroin, but there are currently no research reports on the antibacterial effects of tussah silk fibroin peptides containing RGD sequences. The antibacterial function and corresponding structure-activity relationship of this type of characteristic peptide have not been elucidated.

[0004] The previously authorized patent, "Method for preparing tussah silk fibroin peptides by step-temperature controlled hydrolysis" (ZL201810289358.9), disclosed a process for preparing tussah silk fibroin peptides using the phosphoric acid method, which achieves uniform hydrolysis of tussah silk fibroin through step-temperature settings. However, this process can only obtain mixed peptide products with complex components and cannot directionally separate active peptide monomers with well-defined structures and specific functions.

[0005] In summary, existing technologies have not yet yielded antibacterial peptides derived from tussah silk fibroin with clear amino acid sequences and well-defined antibacterial activity. The lack of a clear active material basis severely restricts the precise application and high-value development of tussah silk fibroin peptides in fields such as antibacterial skincare and wound repair. Summary of the Invention

[0006] This invention provides an antimicrobial peptide derived from tussah silk fibroin, its preparation method, and its application, in order to overcome the above-mentioned problems.

[0007] To achieve the above objectives, the technical solution of the present invention is as follows: In one aspect, the present invention provides an antimicrobial peptide derived from tussah silk fibroin, wherein the amino acid sequence of the antimicrobial peptide is SEQ ID NO:1, SEQ ID NO:2 or SEQ ID NO:3, wherein the SEQ ID NO:1 antimicrobial peptide has an Arg-Gly-Asp sequence, i.e., an RGD sequence.

[0008] Another aspect of the present invention provides a method for preparing the antimicrobial peptide derived from tussah silk fibroin, characterized by comprising the following steps: S1. A mixture of tussah silk fibroin peptides was prepared by phosphoric acid hydrolysis. S2. The polypeptide sequence of the mixed peptides of tussah silk fibroin was identified, and candidate active polypeptides were screened. S3. The candidate active peptides were molecularly docked with Escherichia coli receptor protein 6SPP and Staphylococcus aureus receptor protein 3LUR, respectively, to screen and obtain the antimicrobial peptides derived from the target tussah silk fibroin.

[0009] Further, the specific steps of S1 are as follows: the degummed tussah silk fibroin is mixed with 85% phosphoric acid at a mass ratio of 1:9. The mixture is first dissolved at 20℃-30℃ for 6 h, and then heated to 90℃ for 4 h-8 h for hydrolysis. After the reaction is completed, the hydrolysate is obtained. The hydrolysate is separated and purified to obtain the tussah silk fibroin mixed peptide.

[0010] Furthermore, the separation and purification process employs a combination of nanofiltration and ultrafiltration to fractionate the hydrolysate by molecular weight, collecting peptide components with a molecular weight below 3 kDa as the tussah silk fibroin mixed peptides.

[0011] Further, the specific steps of S2 are as follows: LC-MS / MS is used to identify the polypeptide sequence of the tussah silk fibroin mixed peptide to obtain the amino acid sequence of each polypeptide in the mixed peptide; the identified polypeptide sequences are used to score the activity of a polypeptide activity prediction tool to screen out polypeptides with an activity score ≥50; then the amino acid sequence of the above polypeptides is compared with the known antimicrobial peptide sequences in the APD3 antimicrobial peptide database to screen out polypeptides with a sequence similarity ≥45% and a sequence length of less than 15 amino acid residues as the candidate active polypeptides.

[0012] Further, the specific steps of S3 are as follows: the candidate active peptides screened in step S2 are docked with Escherichia coli receptor protein 6SPP and Staphylococcus aureus receptor protein 3LUR respectively using molecular docking software to screen out peptides that can spontaneously dock with the receptor proteins, which are then used as the antimicrobial peptides derived from tussah silk fibroin.

[0013] Another aspect of the present invention provides the application of the antimicrobial peptide derived from tussah silk fibroin in the preparation of cosmetics.

[0014] The beneficial effects of this invention are: 1. This invention is the first to screen three antibacterial active peptides from tussah silk fibroin hydrolysate. All three peptides can effectively inhibit the growth of Escherichia coli and Staphylococcus aureus, and can disrupt the integrity of bacterial cell membranes and cause leakage of intracellular nucleic acids and proteins, thus exerting antibacterial effects. Among them, the antibacterial peptide containing RGD has the best overall antibacterial effect.

[0015] 2. The antibacterial peptide provided by this invention is derived from natural tussah silk fibroin, has good biocompatibility, and has both antibacterial and skin repair effects, showing good application prospects in the fields of wound care and problem skin care. Attached Figure Description

[0016] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the description of the embodiments or the prior art will be briefly introduced below. Obviously, the drawings described below are some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0017] Figure 1 The diagram shows the molecular docking effects of three antimicrobial peptides with the Escherichia coli receptor protein 6SPP; among them Figure 1 a is SEQ ID NO:1, Figure 1 b is SEQ ID NO:2. Figure 1 c is SEQ ID NO:3; Figure 2 The diagram shows the molecular docking effects of three antimicrobial peptides with the Staphylococcus aureus receptor protein 3LUR; among them Figure 2 a is SEQ ID NO:1, Figure 2 b is SEQ ID NO:2. Figure 2 c is SEQ ID NO:3; Figure 3 The effects of three antimicrobial peptides on bacterial growth curves; among them Figure 3 a represents Escherichia coli. Figure 3 b represents Staphylococcus aureus; Figure 4 The results show the amount of intracellular nucleic acid leakage in bacteria under the action of three antimicrobial peptides. Figure 4 a represents Escherichia coli. Figure 4 b represents Staphylococcus aureus; Figure 5 The results show the leakage of intracellular proteins in bacteria under the action of three antimicrobial peptides. Figure 5 a represents Escherichia coli. Figure 5 b represents Staphylococcus aureus; Figure 6 The results show the effect of tussah silk fibroin peptides on the healing rate of acute wounds in mice. Figure 6 a shows the macroscopic morphological changes in wound healing on days 0, 3, 5, and 7 post-injury in the treatment groups and control groups (K and Y) with different doses (1 mg / bird, 2 mg / bird, 4 mg / bird, and 8 mg / bird) of tussah silk fibroin peptide. Figure 6 b represents the quantitative statistical results of wound healing rates for each group on days 3, 5, and 7. Detailed Implementation

[0018] To make the objectives, technical solutions, and advantages of the embodiments of the present invention clearer, the technical solutions of the embodiments of the present invention will be clearly and completely described below with reference to the accompanying drawings. Obviously, the described embodiments are only some embodiments of the present invention, not all embodiments. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative effort are within the scope of protection of the present invention.

[0019] Example 1: Preparation of antimicrobial peptides derived from tussah silk fibroin S1: Preparation of tussah silk fibroin mixed peptides by phosphoric acid hydrolysis Using degummed tussah silk fibroin as raw material, an 85% phosphoric acid solution was added at a material-to-liquid mass ratio of 1:9. The resulting mixture was stirred and dissolved at 20℃-30℃ for 6 h, then heated to 90℃ and hydrolyzed at a constant temperature for 6 h to obtain tussah silk fibroin hydrolysate. After hydrolysis, the hydrolysate was fractionated using ultrafiltration and nanofiltration membrane modules to remove large molecular weight proteins and inorganic salts, collecting peptide components with a molecular weight below 3 kDa, and freeze-drying to obtain tussah silk fibroin mixed peptides. Degumming can be performed according to existing technology, or the following method can be used: After washing the waste tussah silkworm cocoons with clean water, boil them in a 1% sodium carbonate solution for 1 h to remove the sericin, then bleach them with hydrogen peroxide at 60℃ for 1 h, wash away the alkaline solution and rinsing solution adhering to the silk with water, and dry them at 50℃ to obtain degummed tussah silk fibroin.

[0020] S2: Peptide sequence identification and initial screening The crude tussah silk fibroin peptides were analyzed by LC-MS / MS to obtain the amino acid sequences of all peptides. The obtained peptide sequences were input into the Peptide Ranker peptide activity scoring system for activity prediction, and high-activity peptides with a score ≥50 were screened. The high-activity peptides were then compared with the APD 3 antimicrobial peptide database for sequence similarity, and peptides with a similarity ≥45% to known antimicrobial peptides and a sequence length of less than 15 amino acid residues were selected, resulting in three candidate peptides. The amino acid sequences are shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3, respectively.

[0021] S3: Molecular docking rescreening The amino acid sequences of the three candidate peptides, the crystal structure of Escherichia coli receptor protein 6SPP, and the crystal structure of Staphylococcus aureus receptor protein 3LUR were imported into Discovery Studio 2019 Client software. Molecular docking simulation was performed using the CDOCKER module to calculate the -CDOCKER Energy value of each peptide with the two receptor proteins. The higher the value, the more stable the binding.

[0022] The docking results are shown in Table 1.

[0023] Table 1. Docking energies of three antimicrobial peptides with two bacterial receptors.

[0024] Docking interaction analysis: (1) Interaction with Escherichia coli receptor 6SPP Combination Figure 1 As shown in Table 1, all three polypeptides can dock with the receptor protein of Escherichia coli, with docking energies ranging from 107.93 to 125.56 kcal / mol. Among them, FGRGDGGYG (SEQ ID NO:1) forms hydrogen bonds with the A:LEU13 and A:ASP52 sites of the receptor, and forms hydrophobic interactions with the A:LEU13, A:ALA256, and A:PRO257 sites. AAAAAARRAG (SEQ ID NO:2) A:ALA12, A:LEU13, A:PRO14, A:TYR15, A:ASN17, A:SER19, A:HIS21, A:GLY23, A:HIS24, A:GLU27, A:HIS28, A:ASP52, A:HI S54, A:GLY55, A:THR56, A:PRO57, A:GLN126, A:PRO137, A:ASP138, A:ARG139, A:LYS217, A:GLU220, A:TRP221, A:SER224, A:GLY225, A:GLN227, A:ASP230, A:ARG233, A:TYR237, A:TYR251, A:VAL252, A:TRP253, A:ALA256, A:PRO257, A:TYR260, A:GLY294, A:LYS295,A :ASP296, A:ILE297, A:ILE298, A:TYR299, A:PHE300, A:HIS301, A:HIS323, A:GLY324, A:TYR325, A:VAL326 form hydrogen bonds, AAAAAARRAG (SEQ SEQ ID NO:2) forms electrostatic interactions with sites A:TYR15, A:HIS24, A:GLU27, A:ASP52, A:ASP138, A:ARG139, A:ASP156, A:HIS189, A:LYS217, A:GLU220, A:TRP221, A:TRP229, A:ASP230, A:ARG233, A:TRP253, A:TYR260, A:LYS295, A:ASP296, A:TYR299, A:PHE300, A:HIS323, and A:TYR325; AAAAAARRAG (SEQ ID NO:2) forms hydrophobic interactions with sites A:TRP253 and A:PHE300. GIGGGFGR (SEQ ID NO:3) forms hydrogen bonds with the receptor at sites A:ALA12, A:LEU13, A:PRO14, A:TYR15, A:ASP52, A:ARG139, A:TRP221, A:TYR251, A:VAL252, A:TRP253, A:ALA256, A:PRO257, A:TYR260, A:LYS295, A:ASP296, A:ILE297, A:ILE298, A:TYR299, A:PHE300, and A:HIS301. NO:3) forms electrostatic interactions with sites A:GLU27, A:ASP52, A:ARG139, A:TRP221, A:TYR251, A:TRP253, A:TYR260, A:ASP296, A:TYR299, and A:PHE300. GIGGGFGR (SEQ ID NO:3) forms hydrophobic interactions with sites A:ALA12, A:LEU13, A:PRO14, A:TYR15, A:HIS24, A:HIS28, A:PRO57, A:TRP221, A:TRP229, A:TYR251, A:VAL252, A:TRP253, A:ALA256, A:PRO257, A:TYR260, A:ILE297, A:TYR299, A:PHE300, and A:HIS301.

[0025] (2) Interaction with Staphylococcus aureus receptor 3LUR Combination Figure 2 As shown in Table 1, all three peptides can dock with the receptor protein of Staphylococcus aureus. The docking energy of FGRGDGGYG (SEQ ID NO:1) is -6.83 kcal / mol, and its binding stability with the receptor is slightly lower. The docking energies of the other two peptides are 20.96 and 108.97 kcal / mol, respectively. Specifically, FGRGDGGYG forms hydrogen bonds with the receptor at sites B:GLU64, B:ASN79, B:VAL88, B:ILE89, B:THR90, C:GLY23, C:GLN27, C:TYR71, C:HIS117, C:LYS129, C:SER130, C:PHE134, C:GLU135, and C:LYS156; FGRGDGGYG (SEQ ID NO:1) forms electrostatic interactions with sites C:GLU135 and C:LYS156; and FGRGDGGYG (SEQ ID NO:1) forms hydrophobic interactions with sites C:VAL105, C:PRO106, and C:VAL109. AAAAAARRAG (SEQ ID NO:2) forms hydrogen bonds with the receptor at sites B:THR90, C:GLN27, C:LYS68, C:PRO106, C:GLN110, C:HIS117, C:SER130, C:GLU135, and C:TYR137. GIGGGFGR (SEQ ID NO:3) and its receptors B:SER10, B:THR12, B:LYS17, B:GLU64, B:ASN79, B:SER80, B:ALA81, B:ASP82, B:ILE83, B:ASP87, B:VAL88, B:ILE89, B:THR90, C:GLY23, C:ARG24, C:GLN27, C:ALA31, C:TRP34, C:TYR38, C:GLY59, C:CYS61 Hydrogen bonds are formed at sites C:GLU64, C:GLY67, C:LYS68, C:TYR71, C:PRO106, C:GLN110, C:GLU114, C:HIS117, C:HIS121, C:ALA125, C:VAL128, C:LYS129, C:SER130, C:ALA131, C:PHE133, C:GLU135, C:TYR137, and C:THR142, forming GIGGGFGR (SEQ ID NO: 10 ... GIGGGFGR (SEQ ID NO:3) forms electrostatic interactions with sites B:LYS17, B:GLU64, C:TRP34, C:GLU114, C:PHE133, and C:GLU135. GIGGGFGR (SEQ ID NO:3) forms hydrophobic interactions with sites B:ILE83, B:ALA84, B:VAL88, B:ILE89, C:GLY23, C:ALA26, C:ILE30, C:ALA31, C:TRP34, C:CYS61, C:PRO63, C:GLY67, C:MSE69, C:TYR71, C:PRO106, C:VAL109, C:MSE113, C:HIS117, C:ILE120, C:VAL128, C:PHE133, C:MSE153, and C:PRO154.

[0026] Test Example 1: Bacterial Growth Inhibition Experiment 1. Antibacterial activity assay The antimicrobial activity and minimum inhibitory concentration (MIC) of the antimicrobial peptides shown in SEQ ID NO:1~SEQ ID NO:3 were determined using the micro-broth dilution method. 100 μL of a 1×10⁻⁶ concentration was added to each well of a 96-well plate. 6Bacterial broth medium containing CFU / mL was prepared, and 100 μL of antimicrobial peptide solutions of different concentrations were added to achieve final peptide concentrations of 10.00 mg / mL, 7.50 mg / mL, 5.00 mg / mL, and 2.50 mg / mL, respectively. A blank control group was set up using sterile water to replace the samples. The 96-well plates were incubated at 37±1℃ for 24 h, and the absorbance was measured at 600 nm. Each experiment was repeated in triplicate. The final antimicrobial activity was expressed as the inhibition rate; a higher inhibition rate indicates stronger antimicrobial activity. The calculation formula is as follows:

[0027] In the formula, A 对照 A represents the absorbance value of the blank control group. 实验 The absorbance values ​​are for the antimicrobial peptide treatment group. The lowest peptide concentration at which no bacterial growth is observed with the naked eye is defined as the minimum inhibitory concentration (MIC).

[0028] The antimicrobial effects of the three antimicrobial peptides against *Escherichia coli* and *Staphylococcus aureus* are shown in Tables 1 and 2. The results show that the antimicrobial peptides represented by SEQ ID NO:1 to SEQ ID NO:3 exhibit concentration-dependent inhibitory effects against both *Escherichia coli* and *Staphylococcus aureus*. Within the concentration range tested in this experiment, all three peptides completely inhibited the visible growth of both bacteria at certain concentrations. The minimum inhibitory concentrations (MICs) of the antimicrobial peptides represented by SEQ ID NO:1 to SEQ ID NO:3 against *Escherichia coli* were determined to be 5.00 mg / mL, 7.50 mg / mL, and 5.00 mg / mL, respectively; and the MICs against *Staphylococcus aureus* were 7.50 mg / mL, 7.50 mg / mL, and 5.00 mg / mL, respectively. When comparing antibacterial performance at a concentration of 1×MIC, the antimicrobial peptide represented by FGRGDGGYG (SEQ ID NO:1) showed superior antimicrobial activity against Escherichia coli compared to SEQ ID NO:2 and SEQ ID NO:3. Overall, GIGGGFGR (SEQ ID NO:3) exhibited the strongest antimicrobial efficacy against Staphylococcus aureus, achieving effective antimicrobial activity at lower concentrations.

[0029] Table 1. Antimicrobial effects of the three antimicrobial peptides against Escherichia coli

[0030] Table 2. Antimicrobial effects of the three antimicrobial peptides against Staphylococcus aureus.

[0031] 2. Bacterial growth curve determination Take bacterial suspensions of Escherichia coli and Staphylococcus aureus in the logarithmic growth phase, and add corresponding volumes of each antimicrobial peptide solution to each, so that the final peptide concentration is 1×MIC. Adjust the initial concentration of the bacterial suspension to 1×10⁻⁶. 6 CFU / mL, cultured in a constant temperature shaker at 37℃, absorbance at 600 nm was measured every 2 h from 0 to 12 h, and every 12 h from 12 to 24 h, with each group in triplicate. Bacterial growth curves were plotted with culture time on the x-axis and absorbance on the y-axis.

[0032] The results are as follows Figure 3 As shown, compared with the blank control group, all three antimicrobial peptides inhibited the growth of Escherichia coli and Staphylococcus aureus at a concentration of 1×MIC. Figure 3 a represents Escherichia coli. Figure 3 b represents Staphylococcus aureus. OD values ​​of the two bacteria after 2 hours of peptide treatment... 600 All showed a decrease, indicating a large number of bacterial deaths; among them, the two bacteria in the FGRGDGGYG (SEQ ID NO:1) treatment group only showed slight growth after 10-12 h, with slow overall growth and no obvious logarithmic growth phase, and had the best antibacterial effect; AAAAAARRAG (SEQ ID NO:2) and GIGGGFGR (SEQ ID NO:3) could reduce the growth rate of bacteria in the logarithmic growth phase, and the antibacterial effect of GIGGGFGR (SEQ ID NO:3) was slightly better than that of AAAAAARRAG (SEQ ID NO:2).

[0033] Test Example 2: Cell Membrane Permeability Experiment Take Escherichia coli and Staphylococcus aureus bacterial suspensions in the logarithmic growth phase and adjust the initial bacterial concentration to 1×10⁻⁶. 6 CFU / mL was added to each antimicrobial peptide solution to achieve a final peptide concentration of 1×MIC. The mixture was incubated in a shaker at 37±1℃. Samples of 1 mL were taken at 0 h, 3 h, and 6 h, centrifuged at 8000 r / min for 5 min, and the supernatant was appropriately diluted with sterile water. 200 μL of the diluted solution was then used to measure the absorbance at 260 nm and 280 nm. A blank control group without antimicrobial peptides was included. Each group was tested in triplicate. The absorbance at 260 nm corresponds to the intracellular nucleic acid leakage, and the absorbance at 280 nm corresponds to the intracellular protein leakage, reflecting the degree of bacterial cell membrane damage.

[0034] The results are as follows Figure 4 , Figure 5 As shown ( Figure 4 a, Figure 5 a represents Escherichia coli. Figure 4 b、 Figure 5b represents Staphylococcus aureus. Compared with the blank control group, after treatment with the three antimicrobial peptides, the OD values ​​of Escherichia coli and Staphylococcus aureus were significantly reduced. 260 With OD 280 All three antimicrobial peptides showed an increasing trend with culture time, indicating that they could disrupt the integrity of bacterial cell membranes, causing intracellular nucleic acids and proteins to leak out. Among them, the FGRGDGGYG (SEQ ID NO:1) treatment group showed the largest increase in absorbance, indicating that it had the strongest ability to disrupt bacterial cell membranes, consistent with the aforementioned growth curve experiment results. The AAAAAARRAG (SEQ ID NO:2) and GIGGGFGR (SEQ ID NO:3) treatment groups showed relatively smaller increases in absorbance, indicating that their cell membrane disruptive effect was weaker than that of FGRGDGGYG (SEQ ID NO:1).

[0035] Considering the above indicators such as antibacterial activity, growth inhibition effect, and cell membrane disruption ability, the antibacterial peptide containing the RGD sequence (SEQ ID NO:1) has the best overall antibacterial effect.

[0036] Test Example 3: Acute Wound Healing Experiment in Mice 1. Establishment of an acute wound model Mice were fasted overnight but allowed free access to water. They were then anesthetized with an intraperitoneal injection of 0.4% sodium pentobarbital at a dose of 40 mg / kg, administered in 10 mL / kg volumes. After the mice were anesthetized and no longer exhibited pain reflexes, the fur on their backs was shaved. The shaved areas were washed with warm water. The mice were then fixed prone on the operating table, and an impression was made using a punch approximately 8 mm in diameter. A full-thickness skin excision was then performed along the impression using surgical scissors, maintaining a wound area of ​​50 ± 5 mm². 2 .

[0037] 2. Grouping and administration Mice were randomly divided into 6 groups: a negative control group (K), a positive control group (Y), and 4 dosage experimental groups. The experimental groups used a tussah silk fibroin peptide preparation, which used glycerol and water as a matrix and the tussah silk fibroin mixed peptide prepared in Example 1 as the active ingredient. The core active peptides in the tussah silk fibroin mixed peptide were FGRGDGGYG (SEQ ID NO:1), AAAAAARRAG (SEQ ID NO:2), and GIGGGFGR (SEQ ID NO:3), with a mass ratio of 1:1:1. Preliminary screening determined the dosage of the tussah silk fibroin mixed peptide in the 4 dosage groups to be 1 mg / mouse, 2 mg / mouse, 4 mg / mouse, and 8 mg / mouse, respectively, with 12 wounds in each group. Each mouse in the experimental group received a daily topical application of the tussah silk fibroin peptide preparation to its wounds, with a total volume of 40 µL / mouse / day. The negative control group (K) received an equal volume of matrix, and the positive control group (Y) received an equal volume of Kangfuxin solution. Change the dressing once a day at the same time until the wound heals.

[0038] 3. Statistics on wound healing The wound area of ​​mice was measured and recorded on days 0, 3, 5, and 7. Photographs were taken and the wound area was measured using ImageJ. The wound healing rate (%) was calculated as follows: [(A0-A...] t ) / A0]×100, where A0 is the original area of ​​the wound, A t The wound area is measured on days 3, 5, and 7 after the surgery.

[0039] The results are as follows Figure 6 As shown, the acute wound animal model used in this experiment was an open wound, directly exposed to an infected environment. From Figure 6 The macroscopic morphological changes of the wounds in group a are visible. On days 0, 3, 5 and 7 after modeling, the wounds in each group gradually repaired over time. Figure 6 Quantitative statistical results of wound healing rate showed that the positive group (Y) mice had a higher wound healing rate compared with the blank group (K). In the experimental group, the wound healing effect of the tussah silk fibroin peptide preparation was directly proportional to the concentration when the dosage was less than 4 mg / mouse; however, the wound healing rate decreased when the dosage increased to 8 mg / mouse. On day 7 after modeling, the wound healing in each experimental group was better than that in the blank group, indicating that the mixed peptides derived from tussah silk fibroin provided by this invention can effectively promote wound healing. The antibacterial peptides shown in SEQ ID NO:1, SEQ ID NO:2, and SEQ ID NO:3 are the core antibacterial active peptide segments in this mixed peptide, and are the main active ingredients that exert antibacterial effects, reduce wound infection, and assist wound healing.

[0040] This invention, through targeted screening, has for the first time obtained antimicrobial peptides derived from tussah silk fibroin with well-defined structures. In vitro tests have demonstrated that these peptides exhibit inhibitory activity against both Gram-positive and Gram-negative bacteria, and can exert their effects by disrupting bacterial cell membranes. In vivo experiments have confirmed that the mixed peptides can promote acute wound healing, possessing both antibacterial and repair-promoting effects. This provides a clear material basis and technical support for the high-value application of tussah silk fibroin peptides in antibacterial skincare and wound repair.

[0041] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, and not to limit them; although the present invention has been described in detail with reference to the foregoing embodiments, those skilled in the art should understand that modifications can still be made to the technical solutions described in the foregoing embodiments, or equivalent substitutions can be made to some or all of the technical features; and these modifications or substitutions do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.

Claims

1. An antimicrobial peptide derived from tussah silk fibroin, characterized in that, The amino acid sequence of the antimicrobial peptide is SEQ ID NO:1, and the antimicrobial peptide has an Arg-Gly-Asp sequence, i.e., an RGD sequence.

2. The application of the antimicrobial peptide derived from tussah silk fibroin according to claim 1 in the preparation of cosmetics.

Citation Information

Patent Citations

  • A method for preparing tussah silk fibroin peptides by step-temperature controlled hydrolysis

    CN108276484B

  • Method for preparing functional silk fibroin protein membrane beneficial to cell adhesion

    CN105295080A

  • Method for preparing silk fibroin peptide by separating crystalline region and amorphous region of tussah silk fibroin

    CN118515740A